Business Context and Reporting Period
This Form 8-K Current Report was filed by Transdel Pharmaceuticals, Inc. on September 16, 2011. The filing addresses significant changes in the company's executive leadership effective as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation: John T. Lomoro resigned as Principal Executive Officer, Chief Financial Officer, and Treasurer, effective September 16, 2011.
- Reason for Departure: The resignation was not in connection with any known disagreement with the Company.
- Appointment: Terry Nida, previously the Chief Business Officer, was appointed as the new Principal Executive Officer and Principal Financial Officer on the same date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to expressing appreciation for Mr. Lomoro's dedication and efforts over the past four years.
Investor Verification Checklist
- Verify the effective date of the leadership transition (September 16, 2011).
- Confirm the new titles held by Terry Nida (Principal Executive Officer and Principal Financial Officer).
- Review subsequent filings for any financial impact resulting from the change in financial leadership.
- Note that the registrant name in the filing header is Transdel Pharmaceuticals, Inc., despite the request metadata referencing "HARROW, INC."